Rentscher KE, Carroll JE, Juckett MB, et al. - In this study with 241 adults undergoing allogeneic hematopoietic cell transplantation (HCT) for hematologic cancer, researchers assessed patient-reported depression, sleep disruption, as well as fatigue as risk factors for chronic graft-versus-host disease (cGVHD), disease relapse, and mortality. Participants were asked to self-report measures of depression symptoms, sleep quality, and fatigue (severity, interference) prior to HCT as well as 100 days after HCT. For up to 6 years, clinical results were monitored. As per findings, a greater risk for 6-year relapse and mortality post-HCT was predicted by biobehavioral symptoms, especially sleep disruption and fatigue interference. These symptoms provide specific targets for intervention to better HCT results, because these symptoms are amenable to treatment. cGVHD incidence was not predicted by biobehavioral symptoms.